Background and aims: Transient elastography has been suggested as a possible tool for the non-invasive diagnosis of fibrosis in HCV patients. The aim of this study was to evaluate liver stiffness before antiviral therapy, at the end and after 3 years of follow-up and its role as a possible predictive factor of sustained virological response (SVR). Methods: Liver stiffness was measured before treatment, at the end, and after 3 years of follow-up in 55 HCV patients (32 men and 23 women, age 51.82 ± 11.41 years) treated with peginterferon and ribavirin for either 48 (genotypes 1 and 4) or 24 weeks (genotypes 2 and 3). Results: In virological null responders (12 patients, 21.8%), stiffness values before treatment did not differ from those observed at the end of both therapy or follow-up (9.71±4.26, 10.11±4.68, and 10.19±3.43 kPa, respectively). SVR (30 patients, 54.5%) had mean stiffness values before treatment (10.09±6.85 kPa) which did not differ from those at the end of treatment (8.68±6.38 kPa, p= 0.062), while a significant decrease was observed after three years of follow-up (6.76±4.58, p=0.0141 vs. baseline). In relapsers (7 patients, 12.7%), stiffness values before treatment did not differ from those observed at the end of therapy or follow-up (15.16±8.20, 13.73±7.72, 16.86±10.00kPa, respectively). Pre-treatment stiffness values >12 kPa were significantly associated with no sustained virological response (p< 0.025) with a relative risk of 2.35 (95% CI 1.21 - 4.57) and an attributable risk of 26%. Conclusions: In HCV patients, liver stiffness may be useful to assess the long-term response to treatment. Evaluation of pre-treatment liver stiffness as predictor of SVR may provide an additional tool for patient selection, although it needs to be confirmed in more extensive cohorts.

Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C / C. Stasi; U. Arena; AL. Zignego; G. Corti; M. Monti; E. Triboli; E. Pellegrini; S. Renzo; L. Leoncini; F. Marra; G. Laffi; S. Milani; M. Pinzani. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - ELETTRONICO. - 56:(2012), pp. 1-5. (Intervento presentato al convegno EASL-AASLD Special Conference on Therapy of Hepatitis C: Clinical application and drug development tenutosi a Prague nel September 14-16, 2012).

Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C

STASI, CRISTINA;ZIGNEGO, ANNA LINDA;CORTI, GIAMPAOLO;MONTI, MONICA;MARRA, FABIO;LAFFI, GIACOMO;MILANI, STEFANO;PINZANI, MASSIMO
2012

Abstract

Background and aims: Transient elastography has been suggested as a possible tool for the non-invasive diagnosis of fibrosis in HCV patients. The aim of this study was to evaluate liver stiffness before antiviral therapy, at the end and after 3 years of follow-up and its role as a possible predictive factor of sustained virological response (SVR). Methods: Liver stiffness was measured before treatment, at the end, and after 3 years of follow-up in 55 HCV patients (32 men and 23 women, age 51.82 ± 11.41 years) treated with peginterferon and ribavirin for either 48 (genotypes 1 and 4) or 24 weeks (genotypes 2 and 3). Results: In virological null responders (12 patients, 21.8%), stiffness values before treatment did not differ from those observed at the end of both therapy or follow-up (9.71±4.26, 10.11±4.68, and 10.19±3.43 kPa, respectively). SVR (30 patients, 54.5%) had mean stiffness values before treatment (10.09±6.85 kPa) which did not differ from those at the end of treatment (8.68±6.38 kPa, p= 0.062), while a significant decrease was observed after three years of follow-up (6.76±4.58, p=0.0141 vs. baseline). In relapsers (7 patients, 12.7%), stiffness values before treatment did not differ from those observed at the end of therapy or follow-up (15.16±8.20, 13.73±7.72, 16.86±10.00kPa, respectively). Pre-treatment stiffness values >12 kPa were significantly associated with no sustained virological response (p< 0.025) with a relative risk of 2.35 (95% CI 1.21 - 4.57) and an attributable risk of 26%. Conclusions: In HCV patients, liver stiffness may be useful to assess the long-term response to treatment. Evaluation of pre-treatment liver stiffness as predictor of SVR may provide an additional tool for patient selection, although it needs to be confirmed in more extensive cohorts.
2012
Therapy of Hepatitis C: Clinical Application and Drug Development
EASL-AASLD Special Conference on Therapy of Hepatitis C: Clinical application and drug development
Prague
C. Stasi; U. Arena; AL. Zignego; G. Corti; M. Monti; E. Triboli; E. Pellegrini; S. Renzo; L. Leoncini; F. Marra; G. Laffi; S. Milani; M. Pinzani...espandi
File in questo prodotto:
File Dimensione Formato  
Praga.pdf

Accesso chiuso

Descrizione: Articolo principale
Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 501.95 kB
Formato Adobe PDF
501.95 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/776510
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact